Trial Profile
A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Seizures
- Focus Therapeutic Use
- 23 Apr 2021 Status changed from recruiting to completed.
- 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified April 2019 by Yonsei University).
- 17 Mar 2019 Status changed from not yet recruiting to recruiting.